---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-003880"
form_type: "8-K"
ticker: "BBLG"
cik: "0001419554"
company_name: "Bone Biologics Corp"
filed_at: "2025-04-11T23:59:59+00:00"
generated_at: "2026-05-23T16:05:28.662876+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Bone Biologics receives Nasdaq delisting notice for bid price below $1; plans reverse stock split

## Summary
- Received Nasdaq deficiency letter on April 7, 2025 for failing minimum bid price of $1 per share for 30 consecutive business days.
- Has 180-day compliance period until October 6, 2025 to regain compliance by closing bid price >= $1 for 10 consecutive business days.
- Intends to seek stockholder approval for a reverse stock split at upcoming annual meeting to increase share price.
- No immediate effect on listing; if not compliant, Nasdaq may delist, subject to appeal.

## SEC filing metadata
- accession: 0001641172-25-003880
- form_type: 8-K
- ticker: BBLG
- cik: 0001419554
- company_name: Bone Biologics Corp
- filed_at: 2025-04-11T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1419554/000164117225003880/0001641172-25-003880-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1419554/000164117225003880/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-003880
- JSON: https://secwatch.observer/filing/0001641172-25-003880.json
- Plain text: https://secwatch.observer/filing/0001641172-25-003880.txt

## Key facts
- Listing & Compliance Notices
  Bone Biologics Corp received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).
  - Exchange: nasdaq
  - Notice: deficiency notice
  - Deficiency: minimum bid price
  - Rules: 5550(a)(2), 5810(c)(3)(A)
  source text: April 7, 2025, Bone Biologics Corporation (the “Company”) received a letter from the Listing Qualifications Staff of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, based upon the closing bid price of the Company’s common stock for the last 30 consecutive business days, the Company no longer meets Nasdaq Listing Rule 5550(a)(2), which requires listed companies to maintain a minimum bid price of at least $1 per share. Nasdaq Listing Rule 5810(c)(3)(A) provides a compliance period of 180 calendar days, or until October 6, 2025, in which to regain compliance with the minimum bid price req
  evidence_url: https://www.sec.gov/Archives/edgar/data/1419554/000164117225003880/0001641172-25-003880-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.